{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Very Good Partial Response or better defined as the number of participants with a documented Very Good Partial Response (VGPR) or better as best response per International Myeloma Working Group (IMWG) criteria, measured from date of enrollment through the end of the 8th induction cycle.","groups":[{"description":"Induction Phase: 8 cycles (cycle length of 28 days)\n\n* Daratumumab SC:\n\n  1800mg SC weekly for 8 weeks for Cycle 1 and 2 1800mg SC every 2 weeks on Day 1 and 15 for Cycle 3-6 1800mg SC every 4 weeks on Day 1 for Cycle 7-8\n* Clarithromycin\n\n  500mg PO BID until VGPR or 8 cycles, whichever occurs first\n* Pomalidomide 4mg PO on Days 1-21\n* Dexamethasone 20mg IV as pre-medication on Day 1, 8 40mg PO on the day after daratumumab for Cycle 1 Days 15 and 22 40mg PO pre-daratumumab weekly for Cycle 2-6 20mg PO pre-daratumumab weekly for Cycle 7-8\n\nMaintenance Phase (Cycle 9+): Up to 24 cycles (cycle length of 28 days)\n\n* Daratumumab 1800 mg SC on Day 1\n* Pomalidomide 4mg PO on Day 1-21\n* Dexamethasone 20mg PO pre-daratumumab weekly for Cycles 9 and beyond\n\nDaratumumab SC: Given as 1800mg via injection\n\nClarithromycin: Given as 500mg oral capsule\n\nPomalidomide: Given as 4mg oral capsule\n\nDexamethasone: Given as 20mg IV and 20mg or 40mg oral tablets","id":"OG000","title":"Daratumumab/Clarithromycin/Pomalidomide/Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"up to end of 8th induction cycle (up to approximately 224 days)","title":"Very Good Partial Response Rate or Better Within 8 Cycles of Induction Therapy","type":"PRIMARY","unitOfMeasure":"Participants"}